

INTERNATIONAL CONGRESS ON HEALTH SCIENCES, OCCUPATIONAL HEALTH AND SAFETY-II

APRIL 15-16, 2026 / İĞDIR UNIVERSITY, TÜRKİYE



Editors

Assoc. Prof. Dr. Bahri GÜR

Assist. Prof. Dr. Okan ÖZBAKIR

Copyright © Liberty

Date: 13.05.2026

Liberty Publishing House

Water Street Corridor New York, NY 10038

www.libertyacademicbooks.com

+1 (314) 597-0372

ALL RIGHTS RESERVED NO PART OF THIS BOOK MAY BE REPRODUCED IN ANY FORM, BY PHOTOCOPYING OR BY ANY ELECTRONIC OR MECHANICAL MEANS, INCLUDING INFORMATION STORAGE OR RETRIEVAL SYSTEMS, WITHOUT PERMISSION IN WRITING FROM BOTH THE COPYRIGHT OWNER AND THE PUBLISHER OF THIS BOOK.

© Liberty Academic Publishers 2026

The digital PDF version of this title is available Open Access and distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 license (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits adaptation, alteration, reproduction and distribution for noncommercial use, without further permission provided the original work is attributed. The derivative works do not need to be licensed on the same terms.
adopted by Mariam Rasulan ISBN: 979-8-89695-187-2

ISBN : 979-8-89695-408-8

ADVANCES IN PYRAZOLE DERIVED MOLECULES AS ANTI-CANCER AGENTS

Sayyeda Rushan

Department of Chemistry, Integral University, Lucknow-226026, India

ORCID ID: 0009-0003-7484-4812

Saimah Khan

Department of Chemistry, Integral University, Lucknow-226026, India

ORCID ID: 0000-0002-6483-4325

Abstract:

Pyrazole-derived molecules have gained considerable attention in recent years as promising candidates in anticancer drug discovery due to their structural diversity and wide-ranging biological activities. This study highlights recent advances in the design, synthesis, and biological evaluation of pyrazole-based compounds as antitumor agents. The pyrazole scaffold serves as a versatile pharmacophore capable of interacting with multiple molecular targets involved in cancer progression, including cyclin-dependent kinases, tyrosine kinases, and topoisomerases'. These compounds exhibit significant anticancer activity through mechanisms such as induction of apoptosis, inhibition of cell proliferation, suppression of angiogenesis, and modulation of inflammatory pathways. Recent studies emphasize the importance of structure–activity relationship (SAR) analysis, where strategic substitution and hybridization with other bioactive moieties have led to enhanced potency and selectivity against various cancer cell lines. Furthermore, advancements in drug design approaches, including molecular docking and nanotechnology-based delivery systems, have improved the therapeutic potential of pyrazole derivatives. Although encouraging results have been observed in preclinical studies, several challenges—such as toxicity, limited bioavailability, and hurdles in clinical translation—still need to be addressed. Nevertheless, pyrazole-derived molecules continue to represent a rapidly evolving and promising class of compounds with substantial potential for the development of effective and targeted anticancer therapies.

Keywords: Structure–activity relationship (SAR); Apoptosis; Enzyme inhibition; Cycling-dependent kinases; Tyrosine kinase inhibitors; Drug design; Molecular docking; Cancer therapeutics; Angiogenesis inhibition; Hybrid molecules.